Quang Nguyen, DO
Endocrinology, Diabetes & Metabolism · Henderson, NVNPI 1053516542
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320,108 of the $377,599 with a category attached, or 84.8%. 60 manufacturers reported payments, led by Novo Nordisk at 44.2% of the total. Reporting peaked in 2019 at $101,147 and has fallen 71.5% since, to $28,828 in 2025. Among endocrinology, diabetes & metabolism clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,001 payments — averaging $188.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$167K
- Lilly USA, LLC$56K
- AstraZeneca$45K
- Sanofi-aventis U.S. LLC$44K
- Dexcom, Inc.$22K
- Mannkind Corporation$14K
- plus $31K from 54 others
Across 215 payments — averaging $12,077 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$1.1M
- Eli Lilly$648K
- Novartis$356K
- Amgen$299K
- Mannkind Corporation$71K
- Globus Medical$42K
- plus $29K from 2 others
What the payments were for
- Consulting fees$10,0403%
- Speaking & faculty fees$320,10885%
- Travel & lodging$10,4613%
- Food & beverage$35,87710%
- Education$1,1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$86,940
- JARDIANCE$55,383
- Ozempic$53,924
- FARXIGA$41,431
- SOLIQUA 100/33$21,707
- TOUJEO$20,156
- AFREZZA$12,591
- DEXCOM G6 TRANSMITTER$10,029
- Tresiba$9,551
- TEPEZZA$8,681
- DEXCOM CGM$7,577
- DEXCOM G6 CGM SYSTEM$2,984
- Repatha$785
- PROCLAIM$279
- TZIELD$131
- LEQVIO$125
- MOUNJARO$120
- CRYSVITA$120
- MYCAPSSA$117
- Omnia$114
How this compares
$377,599 in reported general payments places this provider in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $311,144 |
| MounjaroTirzepatide | 124 | $158,692 |
| TrulicityDulaglutide | 86 | $128,066 |
| JardianceEmpagliflozin | 102 | $120,627 |
| ProliaDenosumab | 54 | $93,112 |
| TymlosAbaloparatide | 20 | $66,402 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $49,726 |
| FarxigaDapagliflozin Propanediol | 62 | $46,576 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $46,564 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $43,973 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $42,975 |
| RybelsusSemaglutide | 21 | $36,963 |
| KerendiaFinerenone | 27 | $35,036 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $25,591 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $24,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $167,083 | $348,107193 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $55,893 | $290,831226 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Tradjenta | $2,449 | $202,512163 claims |
| AmgenProlia | $13,368 | $93,11254 claims |
| Radius Health, Inc.Tymlos | $787 | $66,40220 claims |
| AstraZenecaFarxiga | $44,717 | $46,57662 claims |
| BayerKerendia | $699 | $35,03627 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $43,582 | $24,08015 claims |
| AbbVieSynthroid | $1,521 | $8,412100 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $3,021337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Henderson
- William LitchfieldHenderson$288K
- Claudia VogelHenderson$12K
- Omer TararHenderson$5K
- Carlos Hernandez-CassisHenderson$3K
- Amira IbrahimHenderson$2K
- Sehrish WaheedHenderson$835
- Farrukh IqbalHenderson$729
- Nitesh KuhadiyaReno$595K
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.